A new kid on the block of Biotech, Surrozen a preclinical biotech company launched in 2016,  is working on finding regenerative medicine for liver disease. Great news came lately when they manage to acquire an investment of $50 million on their series B round. A financial boost that will drive Surrozen from preclinical to clinal trials, an  assistance they need to reach success. Sure to propel their pipeline in antibody programs for liver disease. Surrozen is creating their own platform where it seems that modulating such a pathway has the potential to treat patients suffering from liver diseases.

Headquarter in San Francisco, Surrozen are actively trying to tap into WNT signaling, and enabling regenerative medicine support and assistance. There are lots of investors in this series B round. Some of them include The Column Group, as well as NS Investment, Hartford Healthcare Endowment and Horizon Ventures, among many others.

Craig Parker, the Surrozen CEO said that there are lots of body tissues which have WNT responsive stem cells. Working on those and bringing in regenerative medicine might seem like a dream right now, but it may become reality in the future and that’s exactly what they are focusing on.

You can find stem cells that participate in regeneration all within our body, be it the liver, GI tract, brain and retina. So there’s a potential to offer regenerative services in the very near future. After this series B round, the company seems to have committed to liver disease research. This niche has seen a lot of activity in recent years, and that’s mostly because it’s so active and comprehensive to begin with. Yet it goes to show that every niche can be a success provided that it’s being worked on adequately and with the right science and financial support.

Surrozen has 2 WNT modulating platforms right now. And they are trying to stimulate the stem cells in the target tissue to create healthy liver cells. These will eventually reverse fibrosis and restore the liver functions. It’s hard to say what type of liver disease they want to work on for the time being, but the potential is there and they just have to make the most out of it. At this time they are investigating retinal disease, gastrointestinal disease as well as kidney disease alongside lung disease.

Cirrhosis in the liver is an example here, because the organ can end up with failure since it’s not able to generate enough tissue to keep itself afloat. While this is only a start, it’s safe to say that it’s a long road for this biotech company. Granted, it will take some time until they refine and adjust everything. Usually those final stretches can be the most challenging ones. But the potential to make a difference is there.